


Stabilis



Phenytoin sodium



Noms commerciaux

Ancolvène	Mexique
Aurantin	Italie
Dalmaril	Mexique
Dilantin	Australie, France
Diphantoïne	Autriche, Belgique, Pays bas
Epamin	Colombie
Epanutin	Allemagne, Autriche, Emirats Arabes Unis, Grande Bretagne, Grèce, Hongrie, Irlande, Pays bas, Pologne, Turquie
Epilog	Egypte
Eptoin	Inde
Etoina	Argentine
Fenaten	Mexique
Fenitem	Mexique
Fenitoina	Argentine
Hidantal	Brésil
Opliphon	Argentine, Colombie
Phenhydan	Allemagne, Autriche, Suisse
Phentolep	Arabie Saoudite
Tremytoïne	Canada



Stabilité des solutions

?		9,2 & 18,4 mg/ml	25°C	?	2			310





























































Facteur influençant la stabilité

				707 3316
				939
				707 3316



Compatibilités

			
			3549
			3824
			921
			1193
			3964
			4528
			3526
		RL	4603
			2141
			2141
			3828
			288
			3012
			198
			1058
			1041
			1703
			201
			3674
			384
			397
			1803
			1974
			496

		Phenytoin sodium : 50 mg/ml Foscarnet sodium : 24 mg/ml	∅	73
		Phenytoin sodium : 10 mg/ml Fosfomycin : 30 mg/ml	▲	4055
		Phenytoin sodium : 50 mg/ml Gentamicin sulfate : 10 mg/ml		789
		Phenytoin sodium : 2 mg/ml Heparin sodium : 50 UI/ml	∅	317
		Phenytoin sodium Hyaluronidase		3617
		Phenytoin sodium Hyaluronidase		3184
		Phenytoin sodium : 50 mg/ml Hydromorphone hydrochloride : 2 >> 40 mg/ml	◆	226
		Phenytoin sodium : 2 mg/ml Hydromorphone hydrochloride : 0.5 mg/ml	◆	1974
		Phenytoin sodium Hydroxocobalamin		3932
		Phenytoin sodium : 5 mg/ml Imipenem-Cilastatin / Relebactam : 5 mg/ml	▲◆	4433
		Phenytoin sodium : 10 mg/ml Isavuconazonium sulfate : 1.5 mg/ml	▲	3829
		Phenytoin sodium : 50 mg/ml Ketamine hydrochloride : 50 mg/ml		2109
		Phenytoin sodium : 50 mg/ml Lansoprazole : 0.55 mg/ml	▲	1625
		Phenytoin sodium : 1 mg/ml Lidocaine hydrochloride : 2 mg/ml	▲◆	619
		Phenytoin sodium : 1 mg/ml Lidocaine hydrochloride : 2 mg/ml	RL	619
		Phenytoin sodium Linezolid		3560
		Phenytoin sodium : 50 mg/ml Linezolid : 2 mg/ml	∅	1925
		Phenytoin sodium : 5 mg/ml Mannitol : 200 mg/ml	▲	3315
		Phenytoin sodium : 50 mg/ml Meropenem : 50 mg/ml	💧	4319
		Phenytoin sodium : 2 mg/ml Methadone hydrochloride : 1 mg/ml	◆	1974
		Phenytoin sodium : 50 mg/ml Micafungin : 1.5 mg/ml	▲	2108
		Phenytoin sodium : 2 mg/ml Morphine sulfate : 1 mg/ml	◆	1974
		Phenytoin sodium Morphine sulfate		3531
		Phenytoin sodium : 50 mg/ml Naloxone hydrochloride : 0.4 mg/ml	∅	3408
		Phenytoin sodium : 1 mg/ml Nitroglycerin : 0.4 mg/ml	▲◆	1049
		Phenytoin sodium Norepinephrine bitartrate		642

		Phenytoin sodium : 6 mg/ml Oritavancin : 0.8 >>2 mg/ml		3152
		Phenytoin sodium Pantoprazole sodium		2090
		Phenytoin sodium : 5 mg/ml Paracetamol		3315
		Phenytoin sodium : 50 mg/ml Paracetamol : 10 mg/ml		4742
		Phenytoin sodium : 50 mg/ml Paracetamol : 10 mg/ml		4435
		Phenytoin sodium Pethidine hydrochloride		3525
		Phenytoin sodium Phenylephrine hydrochloride		3620
		Phenytoin sodium : 10 mg/ml Plazomicin sulfate : 24 mg/ml		4145
		Phenytoin sodium : 50 mg/ml Potassium chloride : 40 mEq/l		730
		Phenytoin sodium : 50 mg/ml Potassium chloride : 40 mEq/l	RL	730
		Phenytoin sodium : 50 mg/ml Propofol : 10 mg/ml		300
		Phenytoin sodium : 50 mg/ml Propofol		660
		Phenytoin sodium : 50 mg/ml Salbutamol sulfate : 1 mg/ml		3216
		Phenytoin sodium : 50 mg/ml Sugammadex : 100 mg/ml		3372
		Phenytoin sodium : 10 mg/ml Sulbactam/durlobactam : 15/15 mg/ml		4801
		Phenytoin sodium : 5 mg/ml Tacrolimus : 1000 µg/ml		479
		Phenytoin sodium : 10 mg/ml Tedizolid phosphate : 0.8 mg/ml		3827
		Phenytoin sodium : 50 mg/ml Vancomycin hydrochloride : 10 mg/ml		3385
		Phenytoin sodium		707
		Phenytoin sodium		3316
		Phenytoin sodium		2074
		Phenytoin sodium		1169
		Phenytoin sodium : 50 mg/ml Temocilline : 83.33 mg/ml		2231
		Phenytoin sodium : 2 mg/ml Theophylline : 4 mg/ml		317
		Phenytoin sodium : 50 mg/ml Thiopental sodium : 25 mg/ml		3767
		Phenytoin sodium : 50 mg/ml Valproic acid : 2 & 20 mg/ml		4428
		Phenytoin sodium : 5 mg/ml Vancomycin hydrochloride : 4 mg/ml		3421

		Phenytoin sodium Vancomycin hydrochloride		3588
		Phenytoin sodium : 50 mg/ml Vasopressin : 0.2 UI/ml		2017
		Phenytoin sodium : 0,5 mg/ml Verapamil hydrochloride : 0,08 mg/ml		706
		Phenytoin sodium : 50 mg/ml		939



Voie d'administration



Bibliographie

	Type	Source
73	Revue	Lor E, Takagi J. Visual compatibility of foscarnet with other injectable drugs. Am J Hosp Pharm 1990 ; 47: 157-159.
198	Revue	Gayed AA, Kheshary PR, Hinkle RL. Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 516-520.
201	Revue	Thompson DF, Allen LV, Stiles ML. Visual compatibility of enalaprilate with selected intravenous medications during simulated Y-site injection. Am J Hosp Pharm 1990 ; 47: 2530-2531.
226	Revue	Walker SE, DeAngelis C, Iazzetta J. Stability and compatibility of combinations of hydromorphone and a second drug. Can J Hosp Pharm 1991 ; 44: 289-295.
288	Revue	Cervenka P, Dejong DJ, Butler BL, Monzingo MD. Visual compatibility of injectable ciprofloxacin lactate with selected injectable drugs during simulated Y-site administration. Hosp Pharm 1992 ; 27: 957-958,961-962.
300	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
310	Revue	Markowsky SJ, Kohls PR, Ehresman D, Leppik I. Compatibility and pH variability of four injectable phenytoin sodium products. Am J Hosp Pharm 1991 ; 48: 510-514.
317	Revue	Kershaw BP, Monnier HL, Mason JH. Visual compatibility of premixed theophylline or heparin with selected drugs for IV administration. Am J Hosp Pharm 1993 ; 50: 1360-1362.
384	Revue	Colucci RD, Cobuzzi LE, Halpern NA. Visual compatibility of esmolol hydrochloride and various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 630-632.
397	Revue	Fong PA, Ward J. Visual compatibility of intravenous famotidine with selected drugs. Am J Hosp Pharm 1989 ; 46: 125-126.

479	Revue	Min DI, Brown T, HWang GC. Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 2964-2966.
496	Revue	Lor E, Sheybani T, Takagi J. Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1991 ; 48: 744-746.
619	Revue	Kirschenbaum HL, Aronoff W, Perentesis GP, Plitz GW, Cutie AJ. Stability and compatibility of lidocaine hydrochloride with selected large-volume parenterals and drugs additives. Am J Hosp Pharm 1982 ; 39: 1013-1015.
642	Revue	Baumgartner TG, Knudsen AK, Dunn AJ, Kilroy RA. Norepinephrine stability in saline solutions. Hosp Pharm 1988 ; 23: 44,49, 59.
660	Revue	Michaels MR, Stauffer GL, Haas DP. Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility. Ann Pharmacotherapy 1996 ; 30: 228-232.
706	Revue	Cutie MR. Compatibility of verapamil hydrochloride with other additives. Am J Hosp Pharm 1981 ; 38: 231.
707	Revue	Carmichael RR, Mahoney CD, Jeffrey LP. Solubility and stability of phenytoin sodium when mixed with intravenous solutions. Am J Hosp Pharm 1980 ; 37: 95-98.
730	Revue	Allen LV, Saul Levinson R, Phisutsinthop D. Compatibility of various admixtures with secondary additives at Y-injection site of intravenous administration sets. Am J Hosp Pharm 1977 ; 34: 939-943.
789	Revue	Garner SS, Wiest DB. Compatibility of drugs separated by a fluid barrier in a retrograde intravenous infusion system. Am J Hosp Pharm 1990 ; 47: 604-606.
921	Revue	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
939	Revue	Gilbar PJ, Groves CF. Visual compatibility of total parenteral nutrition solution (Synthamin 17 Premix*) with selected drugs during simulated Y-site injection. Aust J Hosp Pharm 1994 ; 24: 167-170.
1041	Revue	Hasegawa GR, Eder JF. Visual compatibility of dobutamine hydrochloride with other injectable drugs. Am J Hosp Pharm 1984 ; 41: 949-951.
1049	Revue	Klamerus KJ, Ueda CT, Newton DW. Stability of nitroglycerin in intravenous admixtures. Am J Hosp Pharm 1984 ; 41: 303-305.
1058	Revue	Kirschenbaum HL, Aronoff W, Plitz GW, Perentesis GP, Cutie AJ. Compatibility and stability of dobutamine hydrochloride with large-volume parenterals and selected additives. Am J Hosp Pharm 1983 ; 40: 1690-1691.
1169	Revue	Pfeifle CE, Adler DS, Gannaway WL. Phenytoin sodium solubility in three intravenous solutions. Am J Hosp Pharm 1981 ; 38: 358-362.
1193	Revue	Perentesis GP, Plitz GW, Kirschenbaum HL, Navalakha P, Aronoff W, Cutie AJ. Stability and visual compatibility of bretylium tosylate with selected large-volume parenterals and additives. Am J Hosp Pharm 1983 ; 40: 1010-1012.

1625	Revue	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1703	Revue	Schuster F, Bernard R. Kompatibilität von enalaprilat i.v. mit ausgewählten arzneimitteln. Krankenhauspharmazie 1995 ; 16: 101-103.
1803	Revue	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1925	Revue	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1974	Revue	Chandler SW, Trissel LA, Weinstein SM Combined administration of opioids with selected drugs to manage pain and other cancer symptoms initial safety screening for compatibility. J Pain Symptom Manage 1996 ; 12, 3: 168-171.
2017	Revue	Barker B, Feddema S, Rusho WJ, Dengg R. Visual compatibility of vasopressin with other injectable drugs. Am J Health-Syst Pharm 2005 ; 62: 1969-1976.
2074	Revue	Tse T, Abdullah R. Dissolving phenytoin precipitate in central venous access device. Ann Intern Med 1998 ; 128: 1049.
2090	Revue	Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196.
2108	Revue	Trusley C, Kupiec TC, Trissel LA. Compatibility of micafungin injection with other drugs during simulated Y-site co-administration. Int J Pharm Compound 2006 ; 10: 230-232.
2109	Revue	Pelletier E, Forest JM, Hildgen P. Compatibilité de la kétamine injectable lors de l'administration en dérivé avec d'autres médicaments usuels. Pharmactuel 2006 ; 39: 71-75.
2141	Revue	Barinian N, Chanteux H, Viaene E, Servais H, Tulkens PM. Stability and compatibility study of cefepime in comparaison with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to administration in intensive care units. J Antimicrob Chemother 2003 ; 51: 651-658.
2231	Revue	de Jongh R, Hens R, Basma V, mouton JW, Tulkens PM, Carryn S. Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. J Antimicrob Chemother 2008 ; 61, 2: 382-388.
3012	Revue	Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220.
3152	Revue	Kumar A, Mann HJ. Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration. Am J Health-Syst Pharm 2010 ; 67: 1640-1644.
3184	Laboratoire	Hyaluronidase (Hyalase®) - Summary of Product characteristics.
3216	Revue	de PlasmacvaticastOME, Lavoie A, Forest JM, Leclair G. Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y. Pharmactuel 2011 ; 44, 1 : 14-18

3315	Poster	Louvrier M, Dhennain S, Hocaht S, Zawadski E, Bouffart S, Moquay E. Mise en évidence d'une incompatibilité physico-chimique entre la phénytoïne sodique et le paracétamol injectable en flacon. Communication orale Hopipharm 2012
3316	Revue	Onuki Y, Ikegami-Kawai M, Ishitsuka K, Hayashi Y, Takayama K. A 5% Glucose Infusion Fluid Provokes Significant Precipitation of Phenytoin Sodium Injection via Interruption of the Cosolvent Effect of Propylene Glycol. Chem Pharm Bull 2012 ; 60, 1: 86-93.
3372	Revue	Hanci V, Ali Kiraz H, Ömür D, Ekin S, Uyan B, Yurtlu B.S. Precipitation in Gallipoli: Sugammadex / Amiodarone & Sugammadex / Dobutamine & Sugammadex / Protamine. Rev Bras Anesthesiol 2013 ; 63, 1: 163-166.
3385	Revue	Raverdi V, Ampe E, Hecq JD, Tulkens PM. Stability and compatibility of vancomycin for administration by continuous infusion. J Antimicrob Chemother 2013 ; 68: 1179-1182.
3408	Revue	Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d'autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21.
3421	Revue	Leung E, Venkatesan N, Ly S.C, Scheetz M.H. Physical compatibility of vancomycin and piperacillin sodium–tazobactam at concentrations typically used during prolonged infusions. Am J Health-Syst Pharm 2013 ;70:1163-1166.
3525	Laboratoire	Pethidine hydrochloride - Summary of product Characteristics AMCO Amdipharm Mercury 2012
3526	Laboratoire	Clindamycin (Dalacin®) - Summary of Product Characteristics Pharmacia 2010
3531	Laboratoire	Morphine sulphate 10 mg/mL injection BP – Summary of Product Characteristics Wockhardt 2014
3549	Laboratoire	Amikacine B Braun - Résumé des caractéristiques du produit. B Braun 2012
3560	Laboratoire	Linezolid (Zyvox®) - Summary of Product Characteristics Pharmacia 2013
3588	Laboratoire	Vancomycine (Vancocin®) - Résumé des caractéristiques du produit Sandoz 2011
3617	Laboratoire	Hyaluronidase (Hyalase®) - Summary of Product Characteristics Wockhardt 2011
3620	Laboratoire	Phenylephrine - Summary of Product Characteristics Beacon Pharmaceuticals 2012
3674	Laboratoire	Erythromycin lactobionate - Summary of Product Characteristics PanPharma 2016
3767	Revue	Legris M.E, Lavoie A, Forrest J.M, Hildgen P. Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels. Pharmactuel 2014 ; 47, 3 : 167-172.
3824	Revue	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98
3827	Poster	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015

3828	Poster	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	Poster	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3932	Laboratoire	Hydroxocobalamine (Cyanokit®) - Résumé des caractéristiques du produit Serb Laboratoire 2015
3964	Revue	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33.
4055	Revue	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145	Revue	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4319	Revue	Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4428	Revue	Rashed S.M, Sweatman T.W, Thoma L, Hovinga C.A, Phelps S.J. Chemical Compatibility of Depacon® with Medications Frequently Administered by Intravenous Y-Site Delivery in Patients with Epilepsy or Head Trauma. J Pediatr Pharmacol Ther 2004 ; 9, 2: 126-132.
4433	Revue	Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K. Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications Clin Ther 2020 ; 42, 3: 475-485.
4435	Revue	Hanifah S, Nugroho B.H, Chabib L. Compatibility of acetaminophen with central nervous system medications during simulated Y-site injection. Anaesthesiol Intensive Ther 2020 ; 52, 1: 23-27.
4528	Revue	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4603	Revue	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer's Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.
4742	Revue	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l'acétaminophène injectable avec 102 autres médicaments lors d'une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.
4801	Revue	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:



Dictionnaire

 Antiépileptique	 Injectable
 Noms commerciaux	 Stabilité des solutions
 Contenant	 Molécule
 Concentration	 Température
 Conservation	 Durée de stabilité
 Biosimilaire	 Données conflictuelles
 Bibliographie	 Non précisé
 Chlorure de sodium 0,9%	 Non précisée
 Heure	 Facteur influençant la stabilité
 Solvant	 Glucose 5%
 Provoque	 Précipitation
 Nutrition parentérale (mélange binaire)	 Dégradation
 Diminution	 Compatibilités
 Molécule	 Incompatibilité non précisée
 Incompatible	 Précipitation immédiate
 NaCl 0,9% ou glucose 5%	 Compatible
 Aucun	RL Ringer lactate
 Eau pour préparation injectable	 Précipitation en 1 heure
 Turbidité immédiate	 Précipitation en 4 heures
 Turbidité en 1 heure	 Turbidité à 24 heures
 Précipitation en 15 minutes	 Précipitation en 24 heures
 Instabilité de l'émulsion immédiate	 Instabilité chimique
 Voie d'administration	 Intraveineuse
 Perfusion intraveineuse	 Intramusculaire
 Bibliographie	 Dictionnaire